Health Canada vs the FDA: two very different peptide paths
Published October 26, 2026. Based on law firm and news summaries, cited below. Not legal advice.
Quick take: in 2026 the US moved toward allowing compounding of some peptides while Canada moved toward court orders against unauthorized sales. Same compounds, opposite directions.
Side by side
| Canada | United States | |
|---|---|---|
| Injectable peptides for human use | Regulated as prescription drugs, authorization needed before sale | Some moved to a compounding category in February 2026 |
| 2026 headline | Court injunction against a Québec seller, announced July 29 | Advisory panel voted July 23 and 24 to back six peptides, nonbinding |
| Research use only label | Does not settle the question, per law firms | Reported on products linked to safety problems |
| Status | Position unchanged | Interim policy pending as of October 20 |
Why the gap exists
The US system has a compounding pathway and categories that Canada does not mirror. A law firm summary says the July US recommendations do not apply in Canada.
What does not change on either side
- A compounding category is not an approval.
- Quality and identity still depend on testing, see the COA guide.
- Rules are moving, so recheck anything older than a few months.
Details: the Canadian injunction and the FDA U-turn.
Ready to order?
Paste it in the Promo code box in the order summary at checkout, then press Apply. Confirm the discount line before you pay.
Common questions
Do US peptide decisions apply in Canada?
No. A law firm summary says the US recommendations do not apply here.
Does a research label settle legality?
Not by itself, per law firm write ups.
Which regulator is stricter?
In 2026 Canada was moving toward court enforcement while the US was loosening some compounding. Rules differ.
Sources
- Fasken: Health Canada takes action against unauthorized peptide sales (Aug 2026)
- Gowling WLG: Peptides in Canada (2026)
- AJMC: 5 things to know about the FDA's peptide reversal (Aug 21, 2026)
- REX Shares: The Peptide Market Update, a two-drug story starts to widen (Oct 2026)
Summarised in my own words. Read the originals for the full detail.